A Real-World Experience of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma
Cancers · 30.01.2026 · 18 (3) · 454
DOI: 10.3390/cancers18030454 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 30.01.2026. Verfasst von Matteo Ravara und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIBIT Foundation Onlus, Italian Network for Tumor Bio-immunotherapy (NIBIT) Foundation Onlus.
Abstract (Originalsprache)
Background
Cutaneous squamous cell carcinoma (cSCC) represents the second most common form of non-melanoma skin malignancy, and, when not amenable to curative surgery or radiotherapy, it is a life-threatening disease. The anti-PD-1 monoclonal antibody cemiplimab has transformed the outcome of advanced or metastatic cSCC, with response rates approaching 50% and sustained benefit beyond three years in clinical trials. Cemiplimab is now the first-line standard of care treatment for advanced disease.
Methods
This retrospective observational study included consecutive adult patients with locally advanced (lac) or metastatic (m) cSCC who received cemiplimab (350 mg every three weeks) at the Center for Immuno-Oncology, University Hospital of Siena, Italy, either through an Expanded Access Program or routine clinical practice. Clinical outcome and treatment related adverse events (TRAEs) are reported.
Results
Between December 2019 and December 2023, 27 patients (24 male; median age 82 years [range 41–90]) diagnosed with lacSCC (n = 20 [74.0%]) or mcSCC (n = 7 [25.9%]) were treated with cemiplimab as first line therapy and were followed until June 2024. Head and neck were the primary tumor location for 88.8% of patients, followed by trunk (7.4%) and lower extremities (3.7%). All patients had comorbidities, including six patients (22.2%) with hematologic malignancies. With a median follow-up of 31 months (data cut-off June 2024), the ORR was 66.6% (complete response 22.2%) and the disease control rate (DCR) 77.7%. Median progression-free survival (mPFS) and overall survival (mOS) were not reached, while 2-year PFS and OS rates were 65.2% and 71%, respectively. Treatment was well-tolerated, with three (11.1%) patients experiencing grade ≥3 TRAEs, and three patients discontinuing treatment due to TRAEs.
Conclusions
Our real-world experience confirms the high rate of durable objective responses, good tolerability and long treatment duration of cemiplimab in elderly and frail cSCC patients as well.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.
- Center for Immuno-Oncology, University Hospital of Siena, 53100 Siena, Italy.
- Dermatology Unit, Department of Medicine, Surgery and Neuroscience, University Hospital of Siena, 53100 Siena, Italy.
- Department of Pathology, University Hospital of Siena, 53100 Siena, Italy.
- Maxillofacial Surgery Unit, Department of Medical Biotechnology, University Hospital of Siena, 53100 Siena, Italy.
- Unit of Radiation Oncology, University Hospital of Siena, 53100 Siena, Italy.
ORCID-Profile: Matteo Ravara, Vincenzo D'Alonzo, Monica Valente, Elisa Cinotti, Olindo Massarelli, Roberto Cuomo, Anna Maria Di Giacomo
Förderung
- NIBIT Foundation Onlus
- Italian Network for Tumor Bio-immunotherapy (NIBIT) Foundation Onlus
Zitieren
APA
Ravara, M., Sani, T., D'Alonzo, V., Valente, M., Cinotti, E., Miracco, C., Colucci, M., Croce, V., Carbonari, E., Rana, R., Massarelli, O., Rubino, G., Giannarelli, D., Cuomo, R., Grimaldi, L., Rubegni, P., Maio, M., & Di Giacomo, A. M. (2026). A Real-World Experience of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma. Cancers, 18(3), 454. https://doi.org/10.3390/cancers18030454
Vancouver
Ravara M, Sani T, D'Alonzo V, Valente M, Cinotti E, Miracco C, et al. A Real-World Experience of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma. Cancers. 2026;18(3):454. doi:10.3390/cancers18030454
BibTeX
@article{Ravara2026,
author = {Ravara, Matteo and Sani, Tommaso and D'Alonzo, Vincenzo and Valente, Monica and Cinotti, Elisa and Miracco, Clelia and Colucci, Maura and Croce, Valentina and Carbonari, Eleonora and Rana, Ramiz and Massarelli, Olindo and Rubino, Giovanni and Giannarelli, Diana and Cuomo, Roberto and Grimaldi, Luca and Rubegni, Pietro and Maio, Michele and Di Giacomo, Anna Maria},
title = {A Real-World Experience of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma},
journal = {Cancers},
year = {2026},
volume = {18},
number = {3},
pages = {454},
doi = {10.3390/cancers18030454}
}
EUVIMED